Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20104858 | 0.78 | PKM (0.41) | ALDH1A1SMN1; SMN2LMNAGAAHPGD | |
| SCHEMBL20104863 | 0.77 | KMT2A (0.40) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL20100736 | 0.76 | SMN1; SMN2 (0.44) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL20104904 | 0.76 | POLB (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL20234246 | 0.76 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL20113586 | 0.76 | RAB9A (0.35) | ALDH1A1SMN1; SMN2LMNAHPGDL3MBTL1 | |
| SCHEMBL19033101 | 0.75 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL20100738 | 0.74 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL24938423 | 0.72 | GAA (0.41) | ALDH1A1SMN1; SMN2LMNAMAPTGAA | |
| SCHEMBL20975838 | 0.71 | KMT2A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | PTGIS, NOS2, PTGIR | ALDH1A1 584/4885SMN1; SMN2 4789/4885LMNA 3760/4885 |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | ALDH1A1 584/4885SMN1; SMN2 4789/4885LMNA 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.